The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cisplatin, gemcitabine, and vinorelbine (PGV) compared with cisplatin and etoposide (PE) in the first-line treatment of extensive-stage small-cell lung cancer: Two Brazilian institution experience.
Augusto Akikubo Rodrigues Pereira
No relevant relationships to disclose
Ronnei J F Assis
No relevant relationships to disclose
Emiliano da Costa Pereira
No relevant relationships to disclose
Vladmir C. Lima
No relevant relationships to disclose
Pedro B. Nugue
No relevant relationships to disclose
Jose Rodrigues Pereira
No relevant relationships to disclose